MedTrace Logo

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

NCT02194634 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2016-01-06

No results posted yet for this study

Summary

This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .

Conditions

Interventions

DRUG

Conbercept

Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.

OTHER

Sham injection

Sham intravitreal injection at first month, then repeated as needed.

PROCEDURE

Laser

Laser treatment at first month, then repeated as needed.

OTHER

Sham laser

Sham laser at first month, then repeated as needed.

Sponsors & Collaborators

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-12-31
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02194634 on ClinicalTrials.gov